Mr. Sun is currently the Director of Central BioCity, a Life Science Park in China. He is highly experienced in Business Development, deal making and government relations. Previously, he served as Deputy Director and CTO of China Medical City in China’s Jiangsu Province. Mr. Sun was also Chairman and CEO of Kinogea, and CEO of Nanogea, both focused on Nano-biotech, and Senior VP of Business Development, Marketing and Finance for CapitalBio Corporation, a leading life science company in Beijing China. Among other business ventures, Mr. Sun severed as the Chairman of Shenzhen ChipScreen Biosciences, China’s leading innovative drug developer that has successfully launched Chidamide, an anti-tumor agent. Previously, Mr. Sun was a co-founder and VP of Xeotron, which was acquired by Invitrogen, and he was the head of Business Development of Dendreon. He began his career as a scientist in exploratory research at Amgen. After five years of drug discovery research at Amgen, he became a Senior Analyst/Project Manager in Corporate Business Development, Mergers & Acquisitions. Since 1990’s, Mr. Sun has involved with hundreds of transactions. Mr. Sun received a BS degree in Biology from Lanzhou University in 1983, a MS degree in Molecular Biology from University of Toledo, and a MBA degree from the Anderson School at UCLA in Finance and Management.

David Sun, MBA

Venture Partner